Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples.

Beasley AB, Bentel J, Allcock RJN, Vermeulen T, Calapre L, Isaacs T, Ziman MR, Chen FK, Gray ES.

J Mol Diagn. 2020 Jan 22. pii: S1525-1578(20)30005-2. doi: 10.1016/j.jmoldx.2019.12.005. [Epub ahead of print]

PMID:
31978561
2.

Effect of multidisciplinary rehabilitation on sleep outcomes in individuals with preclinical Huntington disease: An exploratory study.

Bartlett DM, Poudel G, Maddison KJ, Lampit A, Dann L, Eastwood PR, Lazar AS, Ziman MR, Cruickshank TM.

Ann Phys Rehabil Med. 2019 Nov 25. pii: S1877-0657(19)30176-9. doi: 10.1016/j.rehab.2019.11.003. [Epub ahead of print] No abstract available.

PMID:
31778841
3.

Multidisciplinary rehabilitation reduces hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study.

Bartlett DM, Dominguez D JF, Lazar AS, Kordsachia CC, Rankin TJ, Lo J, Govus AD, Power BD, Lampit A, Eastwood PR, Ziman MR, Cruickshank TM.

J Neurol Sci. 2020 Jan 15;408:116522. doi: 10.1016/j.jns.2019.116522. Epub 2019 Oct 13.

PMID:
31665619
4.

Effects of multidisciplinary therapy on physical function in Huntington's disease.

Cruickshank TM, Reyes AP, Penailillo LE, Pulverenti T, Bartlett DM, Zaenker P, Blazevich AJ, Newton RU, Thompson JA, Lo J, Ziman MR.

Acta Neurol Scand. 2018 Dec;138(6):500-507. doi: 10.1111/ane.13002. Epub 2018 Jul 30.

PMID:
30058184
5.

The validity and reliability of using ultrasound elastography to measure cutaneous stiffness, a systematic review.

DeJong HM, Abbott S, Zelesco M, Kennedy BF, Ziman MR, Wood FM.

Int J Burns Trauma. 2017 Dec 20;7(7):124-141. eCollection 2017. Review.

6.

Neuroendocrine and neurotrophic signaling in Huntington's disease: Implications for pathogenic mechanisms and treatment strategies.

Bartlett DM, Cruickshank TM, Hannan AJ, Eastwood PR, Lazar AS, Ziman MR.

Neurosci Biobehav Rev. 2016 Dec;71:444-454. doi: 10.1016/j.neubiorev.2016.09.006. Epub 2016 Sep 13. Review.

7.

Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients.

Zaenker P, Gray ES, Ziman MR.

Autoimmun Rev. 2016 May;15(5):477-83. doi: 10.1016/j.autrev.2016.01.017. Epub 2016 Jan 28. Review.

8.

The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study.

Cruickshank TM, Thompson JA, Domínguez D JF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, Barker RA, Ziman MR.

Brain Behav. 2015 Feb;5(2):e00312. doi: 10.1002/brb3.312. Epub 2015 Jan 15.

9.

A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease.

Cruickshank TM, Reyes AR, Ziman MR.

Medicine (Baltimore). 2015 Jan;94(4):e411. doi: 10.1097/MD.0000000000000411. Review.

10.

Pax genes: regulators of lineage specification and progenitor cell maintenance.

Blake JA, Ziman MR.

Development. 2014 Feb;141(4):737-51. doi: 10.1242/dev.091785. Review.

11.

Serologic autoantibodies as diagnostic cancer biomarkers--a review.

Zaenker P, Ziman MR.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2161-81. doi: 10.1158/1055-9965.EPI-13-0621. Epub 2013 Sep 20. Review.

12.

The characterisation of Pax3 expressant cells in adult peripheral nerve.

Blake JA, Ziman MR.

PLoS One. 2013;8(3):e59184. doi: 10.1371/journal.pone.0059184. Epub 2013 Mar 19.

13.

The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.

Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR.

Eur J Neurol. 2013 Sep;20(9):1325-9. doi: 10.1111/ene.12053. Epub 2012 Dec 7.

PMID:
23216520
14.

Genome-wide discovery of Pax7 target genes during development.

White RB, Ziman MR.

Physiol Genomics. 2008 Mar 14;33(1):41-9. doi: 10.1152/physiolgenomics.00256.2007. Epub 2008 Jan 15.

PMID:
18198279
15.

Pax7 expression in the adult rat superior colliculus following optic nerve injury.

Thomas MG, Barker RA, Beazley LD, Ziman MR.

Neuroreport. 2007 Jan 22;18(2):105-9.

PMID:
17301672
16.

Changing Pax6 expression correlates with axon outgrowth and restoration of topography during optic nerve regeneration.

Rodger J, King CE, Lukehurst S, Chen PB, Dunlop SA, Beazley LD, Ziman MR.

Neuroscience. 2006 Nov 3;142(4):1043-54. Epub 2006 Sep 14.

PMID:
16973301
17.

A comparative analysis of shotgun-cloning and tagged-random amplification-cloning of chromatin immunoprecipitation-isolated genome fragments.

White RB, Ziman MR.

Biochem Biophys Res Commun. 2006 Jul 28;346(2):479-83. Epub 2006 Jun 2.

PMID:
16762317
18.

Pax3 transcripts in melanoblast development.

Blake JA, Ziman MR.

Dev Growth Differ. 2005 Dec;47(9):627-35.

PMID:
16316407
19.

Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma?

Blake J, Ziman MR.

Histol Histopathol. 2003 Apr;18(2):529-39. doi: 10.14670/HH-18.529. Review.

PMID:
12647804
20.

A key role for Pax7 transcripts in determination of muscle and nerve cells.

Ziman MR, Thomas M, Jacobsen P, Beazley L.

Exp Cell Res. 2001 Aug 15;268(2):220-9.

PMID:
11478848
21.

Pax genes in development and maturation of the vertebrate visual system: implications for optic nerve regeneration.

Ziman MR, Rodger J, Chen P, Papadimitriou JM, Dunlop SA, Beazley LD.

Histol Histopathol. 2001 Jan;16(1):239-49. doi: 10.14670/HH-16.239. Review.

PMID:
11193200
22.

Characterization of the alternate allelic forms of human PAX7.

Ziman MR, Pelham JT, Mastaglia FL, Kay PH.

Mamm Genome. 2000 Apr;11(4):332-7. Retraction in: Pelham JT, Kay PH. Mamm Genome. 2001 Dec;12(12):943.

PMID:
10754111
23.

Pax7 is expressed in the capsules surrounding adult mouse neuromuscular spindles.

Rodger J, Ziman MR, Papadimitriou JM, Kay PH.

Biochem Cell Biol. 1999;77(2):153-6.

PMID:
10438150
27.

Alternate Pax7 transcripts are expressed specifically in skeletal muscle, brain and other organs of adult mice.

Ziman MR, Fletcher S, Kay PH.

Int J Biochem Cell Biol. 1997 Jul;29(7):1029-36.

PMID:
9375383
28.

Variegate porphyria in South Africa, 1688-1996--new developments in an old disease.

Hift RJ, Meissner PN, Corrigall AV, Ziman MR, Petersen LA, Meissner DM, Davidson BP, Sutherland J, Dailey HA, Kirsch RE.

S Afr Med J. 1997 Jun;87(6):722-31. Review.

PMID:
9254745
29.

Delta 6-desaturase: improved methodology and analysis of the kinetics in a multi-enzyme system.

Ivanetich KM, Bradshaw JJ, Ziman MR.

Biochim Biophys Acta. 1996 Jan 4;1292(1):120-32.

PMID:
8547334
31.

Inhibition of rat GSH S-transferases by ethylene dibromide.

Ivanetich KM, Ziman MR, Mennie RE, Eidne KA, Corrigall A, Kirsch RE.

Res Commun Chem Pathol Pharmacol. 1984 Aug;45(2):233-42.

PMID:
6385169
32.

1,1,1-Trichloropropene-2,3-oxide: an alternate mechanism for its inhibition of cytochrome P-450.

Ivanetich KM, Ziman MR, Bradshaw JJ.

Res Commun Chem Pathol Pharmacol. 1982 Jan;35(1):111-20.

PMID:
6120542
33.

Reaction schemes for the degradation of cytochrome P-450 by allyl-iso-propylacetamide and fluroxene.

Ivanetich KM, Ziman MR, Bradshaw JJ.

Adv Exp Med Biol. 1981;136 Pt B:1213-20. No abstract available.

PMID:
6124093
34.

Reaction schemes for the degradation of cytochromes P-450 by allyl-isopropylacetamide and fluroxene.

Ivanetich KM, Ziman MR, Bradshaw JJ.

Biochem Pharmacol. 1980 Oct 15;29(20):2805-14. No abstract available.

PMID:
6108115
35.

The effect of fluroxene [(2,2,2-trifluoroethoxy)ethane] on haem biosynthesis and degradation.

Ziman MR, Bradshaw JJ, Ivanetich KM.

Biochem J. 1980 Sep 15;190(3):571-80.

36.

The degradation of different forms of cytochrome P-450 in vivo by fluroxene and allyl-iso-propylacetamide.

Bradshaw JJ, Ziman MR, Ivanetich KM.

Biochem Biophys Res Commun. 1978 Dec 14;85(3):859-66. No abstract available.

PMID:
32885
37.

Organic compounds. Their interaction with and degradation of hepatic microsomal drug-metabolizing enzymes in vitro.

Ivanetich KM, Lucas S, Marsh JA, Ziman MR, Katz ID, Bradshaw JJ.

Drug Metab Dispos. 1978 May-Jun;6(3):218-25. No abstract available.

PMID:
26540

Supplemental Content

Loading ...
Support Center